TW256837B - - Google Patents

Info

Publication number
TW256837B
TW256837B TW082110590A TW82110590A TW256837B TW 256837 B TW256837 B TW 256837B TW 082110590 A TW082110590 A TW 082110590A TW 82110590 A TW82110590 A TW 82110590A TW 256837 B TW256837 B TW 256837B
Authority
TW
Taiwan
Application number
TW082110590A
Other languages
Chinese (zh)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of TW256837B publication Critical patent/TW256837B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082110590A 1992-12-16 1993-12-14 TW256837B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4242459A DE4242459A1 (de) 1992-12-16 1992-12-16 Imidazopyridine

Publications (1)

Publication Number Publication Date
TW256837B true TW256837B (en:Method) 1995-09-11

Family

ID=6475425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082110590A TW256837B (en:Method) 1992-12-16 1993-12-14

Country Status (16)

Country Link
US (1) US5389642A (en:Method)
EP (1) EP0602521A1 (en:Method)
JP (1) JPH06228137A (en:Method)
KR (1) KR940014396A (en:Method)
CN (1) CN1094044A (en:Method)
AU (1) AU665877B2 (en:Method)
CA (1) CA2111362A1 (en:Method)
CZ (1) CZ275893A3 (en:Method)
DE (1) DE4242459A1 (en:Method)
HU (1) HUT66037A (en:Method)
MX (1) MX9307940A (en:Method)
NO (1) NO934622L (en:Method)
PL (1) PL301483A1 (en:Method)
SK (1) SK143593A3 (en:Method)
TW (1) TW256837B (en:Method)
ZA (1) ZA939433B (en:Method)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305602A1 (de) * 1992-06-17 1993-12-23 Merck Patent Gmbh Imidazopyridine
FR2708612B1 (fr) * 1993-08-05 1996-03-01 Roussel Uclaf Nouveaux dérivés bicycliques de l'imidazole, leur procédé de préparation, les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant.
DE4339868A1 (de) * 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
DE4341453A1 (de) * 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
US6060480A (en) * 1996-08-30 2000-05-09 Yoshitomi Pharmaceutical Industries, Ltd. Preventives/remedies for muscle tissue degenerations
DE19845153A1 (de) * 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
RS55023B1 (sr) * 2001-02-24 2016-11-30 Boehringer Ingelheim Pharma Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10327439A1 (de) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
SE532721C2 (sv) 2007-10-01 2010-03-23 Mircona Ab Produkt med vibrationsdämpande keramisk beläggning för spånavskiljning vid materialbearbetning samt metod för dess tillverkning
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
US20250289788A1 (en) * 2022-04-28 2025-09-18 Sds Biotech K.K. Haloalkyl sulfonanilide compound and herbicide containing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036048A (en) * 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5102880A (en) * 1989-05-30 1992-04-07 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5157026A (en) * 1989-05-30 1992-10-20 Merck & Co., Inc. Oxo-purines as angiotensin II antagonists
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
DE4110019C2 (de) * 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE4141788A1 (de) * 1991-12-18 1993-06-24 Merck Patent Gmbh Imidazopyridine
DE4211474A1 (de) * 1992-04-06 1993-10-07 Merck Patent Gmbh Imidazopyridine
DE4305602A1 (de) * 1992-06-17 1993-12-23 Merck Patent Gmbh Imidazopyridine

Also Published As

Publication number Publication date
CZ275893A3 (en) 1994-07-13
US5389642A (en) 1995-02-14
EP0602521A1 (de) 1994-06-22
AU665877B2 (en) 1996-01-18
AU5228693A (en) 1994-06-30
NO934622D0 (no) 1993-12-15
PL301483A1 (en) 1994-06-27
ZA939433B (en) 1994-08-09
HUT66037A (en) 1994-09-28
SK143593A3 (en) 1994-12-07
HU9303601D0 (en) 1994-04-28
KR940014396A (ko) 1994-07-18
CN1094044A (zh) 1994-10-26
DE4242459A1 (de) 1994-06-23
JPH06228137A (ja) 1994-08-16
MX9307940A (es) 1994-08-31
NO934622L (no) 1994-06-17
CA2111362A1 (en) 1994-06-17

Similar Documents

Publication Publication Date Title
DK0598561T3 (en:Method)
TW239916B (en:Method)
TW256837B (en:Method)
NO942869D0 (en:Method)
DK0551248T3 (en:Method)
EP0552625A3 (en:Method)
IN179546B (en:Method)
BR9304651A (en:Method)
DK0599160T3 (en:Method)
DK0596750T3 (en:Method)
DK0574087T3 (en:Method)
DK0576346T3 (en:Method)
DK0554977T3 (en:Method)
DK0588007T3 (en:Method)
TW225999B (en:Method)
DK0571874T3 (en:Method)
DK0564197T3 (en:Method)
DK0581726T3 (en:Method)
TW227078B (en:Method)
DE9209779U1 (en:Method)
FR2687510B1 (en:Method)
FR2699120B1 (en:Method)
AU632452B2 (en:Method)
IN177731B (en:Method)
IN179753B (en:Method)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees